References
Schiffer CA, Schimpff SC. Acute Leukemia. In: Moossa AR, Schimpff SC, Robson MC, editors. Comprehensive Textbook of Oncology, Vol. 2. 2nd ed.: Williams & Wilkins, Maryland, USA, 1991: 1203–11
Dunn CJ, Goa KL. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 1996; 9: 122–47
Liu-Yin JA, Johnson PR, Davies JM, et al. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991 Nov; 79: 415–20
Wahlin A, Hörnsten P, Hedenus M, et al. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother Pharmacol 1991 Oct; 28: 480–3
Hiddemann W, Aul C, Maschmeyer G, et al. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leuk Lymphoma 1993; 10 Suppl.: 133–7
Arlin Z, Case Jr DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990 Mar; 4: 177–83
Berkow R. The Merck Manual, 16th ed. Merck Research Laboratories, Merck & Co., Inc., New Jersey, USA, 1992: 1234–9
Martindale. The Extra Pharmacopoeia, 31st ed. London: Pharmaceutical Press, 1996
1995 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc.
ABPI data sheet compendium, 1994/95. London: Datapharma Publications Ltd, 1994
Rights and permissions
About this article
Cite this article
Mitoxantrone is effective in elderly patients with ANLL. Drugs Ther. Perspect 9, 1–5 (1997). https://doi.org/10.2165/00042310-199709030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199709030-00001